Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation.
Initial confinement of opiate receptors to the nervous system has recently been broadened to several other cell types. Based on the well established hypotensive effect of morphine, we hypothesized that endothelial cells may represent a target for this opiate substance. Endothelial cells (human arterial and rat microvascular) contain a high affinity, saturable opiate binding site presumed to mediate the morphine effects that is stereoselectively and characteristically antagonized by naloxone. This opiate alkaloid-specific binding site is insensitive to opioid peptides. It is, therefore, considered to be the same subtype of opiate receptor (designated mu3) used in the mediation of morphine in other cell types exhibiting the same binding profile. Experiments with endothelial cultures and the aortic ring of rats cultured in vitro demonstrate that morphine exerts direct modulatory control over the activities of endothelial cells, which leads to vasodilation. It induces the production of nitric oxide, a process that is sensitive to naloxone antagonism and nitric oxide synthase inhibition. In contrast with that of opiates, the administration of opioid peptides does not induce nitric oxide production by endothelial cells. In conclusion, the data presented above reveal a novel site of morphine action, endothelial cells, where a mu3 receptor is coupled to nitric oxide release and vasodilation.
Cardiac Research Program, University Medical Center, State University of New York, Stony Brook 11794, USA.
G B
GB
Stefano
A
A
Hartman
T V
TV
Bilfinger
H I
HI
Magazine
Y
Y
Liu
F
F
Casares
M S
MS
Goligorsky
D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000502:physiology; D001158:Arteries; D001667:Binding, Competitive; D002478:Cells, Cultured; D004090:Dihydromorphine / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D009294:Narcotics / Q000494:pharmacology; D009569:Nitric Oxide / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000032:analysis / Q000187:drug effects / Q000378:metabolism*; D014664:Vasodilation
D004745:Enkephalins; D009294:Narcotics; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009569:Nitric Oxide; D009020:Morphine; D004090:Dihydromorphine